These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Potential Docking Affinity of three Approved Drugs against SARS-CoV-2 for COVID-19 treatment.pdf (1.33 MB)

Potential Docking Affinity of Three Approved Drugs Against SARS-CoV-2 for COVID-19 Treatment

submitted on 23.06.2020, 17:21 and posted on 25.06.2020, 13:01 by Venkata Rachakulla, Hemanjali Rachakulla

Potential Docking Affinity of three Approved Drugs against

SARS-CoV-2 for COVID-19 treatment.

Venkata Sambasiva Rao Rachakulla1, Hemanjali Devi Rachakulla2

1Department of Math, Greene County High School, Greensboro, GA, 30642 USA.

2Department of Science, Jonesboro High School, Jonesboro, GA, 30236, USA.

1Author for correspondence email:

2Author email:


Objectives: The availability of a safe and effective drug for COVID-19 is well-recognized as an additional tool to contribute to the control of the pandemic. At the same time, the challenges and efforts needed to rapidly develop, evaluate, and produce this at scale are enormous. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable.

Methods: In this study, we have measured the virtual interaction of crystal data structures of protein downloaded from protein data bank (PDB ID 7BRP) with corticosteroid drug candidates approved by FDA for other medical purposes which have less side effects. The results are analyzed in contrast some drugs candidates currently using for the treatment of COVID-19.

Results: The binding energies in kilocalories/mole obtained from the docking of 7BRP protease with ligands under investigation Betamethasone Phosphate (-6.9), Fluticasone (-6.1) and Dexamethasone (-5.9) and also with currently using drug candidates Remdesivir(-6.5), Lopinavir (-6.0), Baceprivir(-5.7), Rabavirin(-6), Ritinovir(-5.3), Hydroxyquinoline(-5.0), Chloroquine (-4.7), Oseltamivir(-4.6), Favipiravir(-3.9).

Discussion: The docking results suggest a higher binding affinity of the drug molecules under investigation against SARS-CoV-2 in contrast with other drug candidates currently being used for the treatment of COVID-19. We have analyzed bond interactions of protein-ligand from images in 10 modes of investigated drugs in contrast with Remdesivir and also discussed the advantages of inhalation methods of drug fluticasone.

Conclusion: From this study, it can be suggested that these drugs are promising candidates for antiviral treatment with high potential to fight against SARS-CoV-2 strain keeping in view various ways of administration of drugs currently practicing.




Email Address of Submitting Author


Greene County High School



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of Interest